-
Approved Drugs for SCD May Not Be Cost-Effective in US, Report Says
Approved therapies for sickle cell disease in the U.S. may not be cost-effective at their current prices, according to a draft report by ICER. Learn more here.
Do you find it challenging to pay for your SCD therapies?
Sorry, there were no replies found.
Log in to reply.